A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesMatthew S. Davids, Alexey V. Danilov, Richard Ghalie et al.|Blood Advances|2024Cited by 9